NEWS
All News
Special Reports
CONFERENCES
Conference Coverage
Conference Listing
MEDIA
All Videos
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Medical World News
Podcasts
Precision Medicine
PUBLICATIONS
All Publications
Evolving Paradigms
Roundtable Meetings Spotlight
Targeted Therapies in Oncology
CME/CE
RESOURCES
Case-Based Roundtable Series
Clinical Trials
Partners
Precision Medicine Perspectives
Press Releases
Sponsored Content
Treatment Resources
SUBSCRIBE
eNewsletter

logo
Featured Clinical Focus
AML
BTK Inhibitors: In-Focus
Biomarker-Driven Lung Cancer
Bone Marrow & SCT
CAR T-Cell Therapy
Chronic Lymphocytic Leukemia
EGFR-Positive Lung Cancer
Endometrial Cancer
Follicular Lymphoma
HCC
Lung Cancer
MPNs
Mantle Cell Lymphoma
Multiple Myeloma
Renal Cell Carcinoma
Small Cell Lung Cancer
Thyroid Cancers
Clinical Focus
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Cancers
Head & Neck Cancers
Hematology
Leukemias
Lung Cancer
Lymphomas
Melanoma
Sarcoma
Skin Cancers
Thyroid Cancers
Spotlight
Case Based Peer Perspectives
Case-Based Roundtable Series
Clinical Trials
Podcasts
Precision Medicine
Special Reports
All News
Special Reports
Conference Coverage
Conference Listing
All Videos
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Medical World News
Podcasts
Precision Medicine
All Publications
Evolving Paradigms
Roundtable Meetings Spotlight
Targeted Therapies in Oncology
CME/CE
Case-Based Roundtable Series
Clinical Trials
Partners
Precision Medicine Perspectives
Press Releases
Sponsored Content
Treatment Resources
eNewsletter
Advertisement
BIOMARKER-DRIVEN LUNG CANCER
| BONE MARROW & STEM CELL TRANSPLANT
| GYNECOLOGIC CANCERS
| HEMATOLOGY
| LUNG CANCER
| SMALL CELL LUNG CANCER
| THYROID CANCERS
| BRAIN CANCER
| BREAST CANCER
| CAR T-CELL THERAPY
| ENDOMETRIAL CANCER
| GASTRIC CANCER
| GENITOURINARY CANCERS
| GENOMIC TESTING
| GI CANCERS
| HCC
| HEAD & NECK CANCERS
| IMMUNOTHERAPY
| LEUKEMIAS
| LYMPHOMAS
| MET-TARGETED THERAPY
| NTRK GENE FUSIONS
| SARCOMA
| SKIN CANCERS
View All >>
  • BIOMARKER-DRIVEN LUNG CANCER
  • BONE MARROW & STEM CELL TRANSPLANT
  • BRAIN CANCER
  • BREAST CANCER
  • CAR T-CELL THERAPY
  • ENDOMETRIAL CANCER
  • GASTRIC CANCER
  • GENITOURINARY CANCERS
  • GENOMIC TESTING
  • GI CANCERS
  • GYNECOLOGIC CANCERS
  • HCC
  • HEAD & NECK CANCERS
  • HEMATOLOGY
  • IMMUNOTHERAPY
  • LEUKEMIAS
  • LUNG CANCER
  • LYMPHOMAS
  • MET-TARGETED THERAPY
  • NTRK GENE FUSIONS
  • SARCOMA
  • SKIN CANCERS
  • SMALL CELL LUNG CANCER
  • THYROID CANCERS

SPOTLIGHT -

Case Based Peer Perspectives
| Case-Based Roundtable Series
| Clinical Trials
| Podcasts
| Precision Medicine
| Special Reports

June 2017

home / publications / targeted-therapy-news / june-2017

Combinations Offer Potential to Overcome Resistance in HER2+ Breast Cancer

Combinations Offer Potential to Overcome Resistance in HER2+ Breast Cancer

June 20th 2017
ArticleClinical Articles

C. Kent Osborne, MD, outlines current strategies for overcoming resistance to HER2-targeted agents in early breast cancer.


The Choice Between Immunotherapy and TKIs for Liver Cancer

The Choice Between Immunotherapy and TKIs for Liver Cancer

June 20th 2017
ArticleClinical Articles

Options for treating patients with hepatocellular carcinoma may currently be limited, with most physicians turning to a tyrosine kinase inhibitor for advanced disease, but physicians may soon be able to choose between a TKI and immunotherapy.


The Debate Over Upfront Use of Newer Targeted Agents in NSCLC

The Debate Over Upfront Use of Newer Targeted Agents in NSCLC

June 19th 2017
ArticleClinical Articles

Two oncologists offer rationale for both sides of the argument for/against the upfront use of newer tyrosine kinase inhibitors for patients with ALK-positive or EGFR-mutant NSCLC.


The Rapid Uptake of Immunotherapy in Bladder Cancer

The Rapid Uptake of Immunotherapy in Bladder Cancer

June 16th 2017
ArticleClinical Articles

Immunotherapy agents have been rapidly absorbed into the treatment paradigm for various cancer types. Nowhere is this more obvious than in the treatment for patients with bladder cancer. In May alone, 3 checkpoint inhibitors were approved for use in bladder cancer, bringing the total of checkpoint inhibitors approved in this field to 5 agents.

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.